Should You Buy RedHill Biopharma Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, RedHill Biopharma Ltd. (RDHL) scores 4.1/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.58, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 1 of 1 CirclFi valuation models project upside for RedHill Biopharma Ltd. (RDHL) at $0.58 — the model consensus leans bullish, with a Quality Score of 4.1/10 and Value-Trap risk of 50/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for RedHill Biopharma Ltd. (RDHL) in 2026?
What Is the Bull Case vs the Bear Case for RedHill Biopharma Ltd. (RDHL)?
| Bull case — $2.74 target (+376.6%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +376.6% across 1 bullish models from the current price of $0.58. | No active model flags significant downside for RDHL. The Value Trap score of 50/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $2.74 (+376.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for RedHill Biopharma Ltd.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. |
How Does RDHL Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: PTPI · KAYS · GRPS · SHPH · INM · NIKA · SIGA · CPIX · YCBD · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like RDHL on Quality?
Closest companies to RDHL’s Quality of Company score of 4.1/10, across all industries.
- NGEN — NervGen Pharma Corp. (QOC 4.1) · analysis
- BLIV — BeLive Holdings (QOC 4.1) · analysis
- CRCW — The Crypto Company (QOC 4.1) · analysis
- TENX — Tenax Therapeutics, Inc. (QOC 4.1) · analysis
- TRXA — T-REX Acquisition Corp. (QOC 4.1) · analysis
- ARTL — Artelo Biosciences, Inc. (QOC 4.1) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does RDHL Appear In?
So Is RedHill Biopharma Ltd. (RDHL) Worth Buying in 2026?
The convergence of 4.1/10 quality, multi-model undervaluation (1/1 bullish, +376.6% median upside), and a median fair value of $2.74 vs. $0.58 current price makes RedHill Biopharma Ltd. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. RedHill Biopharma Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About RDHL Stock?
Should I buy RDHL stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for RDHL at $0.58. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.1/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in RedHill Biopharma Ltd.?
Key risks include: an elevated Value Trap score of 50/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.1/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does RDHL compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, RDHL holds a Quality Score of 4.1/10. Comparable companies include PTPI (QOC 4.1), KAYS (QOC 3.9), GRPS (QOC 4.1). The relative ranking helps investors identify whether RDHL offers better fundamental quality than alternatives in the same sector.
Is RDHL a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RDHL's Quality Score of 4.1/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy RDHL at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $2.74 to $2.74. At $0.58, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for RDHL.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad